Hepatocellular Carcinoma

On this page

HCC Basics - Liver's Dark Side

  • Definition: Primary malignancy of the liver arising from hepatocytes.
  • Epidemiology: 6th most common cancer worldwide; 3rd leading cause of cancer death. Significant burden in India due to Hepatitis B (HBV) & C (HCV) prevalence.
  • Risk Factors:
    • Chronic Viral Hepatitis (HBV, HCV)
    • Alcoholic Liver Disease
    • Non-alcoholic Fatty Liver Disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)
    • Aflatoxin B1 exposure (e.g., contaminated groundnuts, corn)
    • Cirrhosis (present in ~80-90% of HCC cases, from any cause)
    • 📌 Mnemonic: 'HH AAN' (HBV, HCV, Alcohol, Aflatoxin, NAFLD)

⭐ Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, accounting for approximately 75-85% of all primary liver cancers globally.

Diagnosis - Spotting the Enemy

  • Screening (High-Risk: Cirrhosis, Chronic HBV/HCV):
    • Ultrasound (USG) every 6 months.
    • Serum Alpha-fetoprotein (AFP); ↑AFP > 20 ng/mL is abnormal.
  • Diagnostic Imaging (Key):
    • Multiphase CT or MRI (preferred):
      • Hallmark: Arterial Phase Hyperenhancement (APHE) & Portal/Venous Phase Washout.
    • LI-RADS (Liver Imaging Reporting and Data System) used for characterization. LI-RADS table and CT images of HCC
  • Tumor Markers:
    • AFP > 400 ng/mL highly suggestive.
    • Others: AFP-L3, PIVKA-II (DCP).
  • Biopsy:
    • For LI-RADS 3/4 or indeterminate lesions.
    • If imaging non-diagnostic, or in non-cirrhotic liver.
    • Risk: Needle-track seeding.

⭐ In cirrhotic patients, classic imaging features (arterial phase hyperenhancement and portal/venous phase washout) are diagnostic for HCC, often obviating biopsy.

Staging & Prognosis - Sizing Up Trouble

  • Core Principle: Staging dictates therapy & predicts survival.
  • BCLC (Barcelona Clinic Liver Cancer): Gold standard.

    ⭐ The Barcelona Clinic Liver Cancer (BCLC) staging system is preferred as it links stage with treatment strategy and prognosis.

  • BCLC Stages & Treatment:
    • 0 (Very Early) / A (Early): Curative intent (resection, transplant, RFA).
    • B (Intermediate): TACE.
    • C (Advanced): Systemic therapy (e.g., Sorafenib, Lenvatinib).
    • D (Terminal): Best supportive care.
  • Key Prognostic Factors:
    • Tumor burden: Size, number, vascular invasion (MVI).
    • Liver function reserve: Child-Pugh score.
    • Patient's overall health: ECOG performance status.
    • Serum Biomarkers: AFP levels.

Treatment - Battle Plan

  • BCLC 0 & A (Very Early & Early Stage): Curative Intent
    • Surgical Resection: Child-Pugh A, adequate liver reserve.
    • Liver Transplantation: 📌 Milan Criteria: Single tumor ≤5 cm, or up to 3 tumors each ≤3 cm; no macrovascular invasion; no extrahepatic spread.
    • Ablation (RFA/MWA): For tumors <3 cm, non-surgical candidates.
  • BCLC B (Intermediate Stage): Loco-regional Therapies
    • TACE (Transarterial Chemoembolization): Multinodular, preserved liver function.
    • TARE/SIRT (Y-90 Radioembolization): Alternative for TACE-unsuitable/refractory.
  • BCLC C (Advanced Stage): Systemic Therapy
    • Atezolizumab + Bevacizumab (Preferred 1st line).
    • TKIs (Sorafenib, Lenvatinib).
  • BCLC D (Terminal Stage): Best Supportive Care.

HCC Treatment Algorithm based on BCLC Staging

⭐ For advanced HCC (BCLC C), Atezolizumab-Bevacizumab is a preferred first-line systemic therapy, showing improved survival over Sorafenib monotherapy.

High‑Yield Points - ⚡ Biggest Takeaways

  • Chronic Hepatitis B & C and cirrhosis are major risk factors for HCC.
  • Screening in high-risk patients involves serum AFP and ultrasound every 6 months.
  • Diagnosis often relies on characteristic imaging: arterial phase hyperenhancement and venous/delayed phase washout on CT/MRI.
  • Milan criteria (single tumor ≤5 cm, or up to 3 tumors each ≤3 cm) are key for liver transplant eligibility.
  • Surgical resection offers the best chance for cure in non-cirrhotic patients or those with well-compensated cirrhosis and solitary tumors.
  • TACE (Transarterial Chemoembolization) is a primary palliative treatment for unresectable, localized HCC.
  • Sorafenib and Lenvatinib are first-line systemic therapies for advanced HCC with preserved liver function.

Practice Questions: Hepatocellular Carcinoma

Test your understanding with these related questions

A patient with a history of alcohol dependence syndrome presents with sudden and unintentional weight loss. What is the most likely diagnosis?

1 of 5

Flashcards: Hepatocellular Carcinoma

1/10

The risk of rupture in hepatic adenoma is estimated to be seen in _____% to 50% of the cases

TAP TO REVEAL ANSWER

The risk of rupture in hepatic adenoma is estimated to be seen in _____% to 50% of the cases

30

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial